Phase 4 N=8 A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy
Psoriasis
Primary: Investigator Global Assessment — 1.13 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=21 Psoriasis Inflammation and Systemic Co Morbidities
Psoriasis
Primary: Change in Histology
Phase 3 N=159 A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)
Psoriasis
Primary: Number of Participants Who Achieve a Greater Than or Equal to 75% Improvement in Psoriasis Area and Severity Index (PASI) Score — 111; 111 Participants
Phase 4 N=20 Topical Psoriasis Study for Patients Receiving Biologic Therapy
Psoriasis
Primary: Psoriasis Severity — 4.25 units on a scale
Phase 2 N=176 Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy
Chronic Plaque Psoriasis
Primary: Achievement of Psoriasis Activity and Severity Index (PASI75) Response at Week 12 — 6.8; 74.6; 82.8 percentage of subjects — p=<0.001
Phase 3 N=730 Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment
Chronic Plaque Psoriasis
Primary: Percentage of Participants Who Achieve a PASI75 Response at Week 16 Compared With Baseline (Week 0) — 70.9; 64.8 percentage of participants — p=0.086
N/A N=103 A Study of Effectiveness and Safety of Tumor Necrosis Factor (TNF) Inhibitors in Patients With Moderate to Severe Psoriasis
Psoriasis
Primary: Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score — 48.65; 75.70; 87.85; 90.29 Percent change
Phase 4 N=352 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
Psoriasis
Primary: Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at…
Phase 4 N=210 A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis
Psoriasis Vulgaris
Primary: Having Least 75% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 75 Response) From Baseline at Week 24 — 85; 40 Participants — p=<0.001
Phase 3 N=120 A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy
Psoriasis
Primary: Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI90) at Week 24 — 10.0; 83.3 percentage of participants — p=< 0.001
Phase 2 N=9 Acitretin and Etanercept in Psoriasis
Psoriasis
Primary: Percent of Patients Achieving PASI 75 at 6 Months After the Addition of Acitretin Therapy — 12.5 percent
Phase 4 N=39 Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies
Psoriasis
Primary: Number of Patients With Physician's Global Assessment (sPGA) Score 0 or 1 — 24 Participants
Phase 3 N=327 Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Percentage of Participants With a 90% Reduction From Baseline Psoriasis Area and Severity Index (PASI 90) at Week 16 — 65.6; 73.8 percentage of participants
Phase 3 N=162 A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment
Plaque Psoriasis
Primary: Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) at Week 24 — 90.7; 22.2; 70.4 Percentage of Participants — p=<.0001
Phase 4 N=1,266 A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies
Psoriasis
Primary: Percentage of Participants With Physician's Global Assessment (PGA) Ratings of Good or Better (FT) — 68.0 percentage of participants
Phase 4 N=124 Moderate to Severe Plaque Psoriasis With Scalp Involvement
Psoriasis
Primary: Percentage Change From Baseline in Psoriasis Scalp Severity Index at Week 12 — 20.4; 86.8 Percent change — p=<0.0001
Phase 3 N=202 Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.
Psoriasis
Primary: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75 Response at Week 24 — 89.52; 33.68 Percentage of participants — p=<.0001
N/A N=18 Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.
Psoriasis
Primary: Percentage Change in Endothelial Function Compared to Baseline. — -1.414 percent change — p=<0.05
Phase 2 N=19 Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis
Psoriasis
Primary: Subjects With >=75% Reduction in Baseline Psoriasis Area and Severity Index (PASI) (Efficacy) — 3; 1 Participants — p=0.43
Phase 3 N=868 The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)
Psoriasis
Primary: Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16. — 0.78; 0.42 Proportion of participants — p=<0.001
Phase 3 N=213 An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis
Moderate to Severe Plaque Psoriasis
Primary: • The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment — 66; 70; 0 Participants
Phase 4 N=29 Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis
Plaque Psoriasis
Primary: Number of Participants Maintaining Psoriasis Area Severity Index Score (PASI) 75 at Week 36 — 4; 2 participants
Phase 3 N=15 A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis
Palmoplantaris Pustulosis
Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change
Phase 4 N=38 A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)
Psoriasis
Primary: Psoriasis Area and Severity Index (PASI) 75 Response Rate at Week 10 — 71 Percentage of participants
Phase 4 N=12 A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis
Psoriatic Nail · Psoriasis Vulgaris · Psoriasis
Primary: Mean Percent Change of mNAPSI (Modified Nail Area Psoriasis Severity Index) at Week 36 Compared to Baseline for All Nails. — 64.1 percentage of reduction in mNAPSI score…
N/A N=660 Assessment of Long-Term Infliximab for Psoriasis (P05319)
Psoriasis
Primary: Number of Participants With a Psoriasis Area Sensitivity Index (PASI)-75 Response at Week 50 — 296 Participants
Phase 2 N=46 Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
Psoriasis · Plaque Psoriasis
Primary: Safety - Treatment Emergent Adverse Events (TEAEs) - Number of TEAEs — 27; 32; 0; 0 TEAEs
Phase 3 N=24 Safety and Efficacy of Infliximab in Palmoplantar Psoriasis
Palmoplantar Psoriasis
Primary: 75% Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) From Day 0 — 1; 4 Participants
Phase 3 N=219 Subject Preference for Scalp Psoriasis Treatment
Scalp Psoriasis
Primary: Percentage of Subjects Preffering Clobetasol Propionate Shampoo Better Than Comparator — 28.5; 31.6; 21.8 Percentage of participants — p=0.0003
Phase 1 N=29 A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
Psoriasis
Primary: Percentage (%) of Participants Who Achieved Greater Than or Equal (>=) to 75% Improvement From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12 — 5; 0…